ALSPW Spineway SAS

Spineway Expansion in Asia

Spineway Expansion in Asia

Press release                                                                           Ecully, February 11th, 2021 – 6:30 p.m.



Continued expansion in Asia :

  • First implantation of the Mont Blanc 3D+ in Thailand
  • Signature of an Exclusive Distribution Agreement in Malaysia

Spineway, specialized in the treatment of severe disorders of the spine, announces the first surgery in Thailand with Mont Blanc 3D+ instrumentation as well as the signature of an exclusive distribution agreement for the marketing of its products in Malaysia.

This operation was successfully performed on February 4th, 2021 by Dr Chatchawarl Sarntipiphat, orthopedic surgeon at Srinagarind University Hospital in Khon Kaen Province, Thailand, on an 11-year-old patient with idiopathic scoliosis.

Doctor Sarntipiphat specifies the context of this operation : “This type of scoliosis requires a surgical correction because the permanent deviation of the spine can cause a deformation of the vertebral bodies, especially during the child's growth period. Particularly indicated for this type of pathology, Spineway's patented Mont Blanc 3D+ implant makes it possible to correct the deformity while keeping the natural curves of the spine.”

Present in Thailand since 2016 through exclusive distribution, Spineway continues to develop its know-how on the Asian continent with the implementation of a national distribution agreement within the main healthcare centers in Malaysia, a few months after the signing of an exclusive commercial agreement for the sale of its products in Japan1. Spineway and its partner will promote and introduce the whole product portfolio, in particular, the specific solutions for mini-invasive surgery Mont-Blanc MIS.

Stéphane Le Roux, CEO of Spineway, says : “We are delighted with this partnership in Malaysia, a country recognized as having one of the best healthcare systems in Asia. Our Mont-Blanc MIS and MISTI platform designed by Spineway will address the market needs by providing advanced surgical techniques to surgeons and patients”.

Sales are scheduled to start in June 2020, immediately after the product registration will be granted by the Medical Device Authority in Malaysia.

This first implantation of the Mont Blanc 3D+ in Thailand and this new distribution agreement in Malaysia demonstrate that Spineway continues its development in Asia thanks to the high added value of its technologies. 

Upcoming: April 15th, 2021 - Publication of first quarter 2021 revenues

March 8th, 2021 – General meeting

The annual accounts and and the preparatory documents for the Shareholders' Meeting

are available on the company’s website in the Investors

SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.

Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).

ISIN: FR0011398874 - ALSPW

Contacts:

SPINEWAY



Shareholder-services line

Available Tuesday through Thursday

(10 a.m. – 12 p.m.)

+33 (0)811 045 555
Eligible PEA / PME



ALSPW





Euronext Growth





AELIUM 



Finance & Communication



Investor relations

Solène Kennis








1



Attachment



EN
11/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accéléra...

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%) Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros20252024Variation en %CA 1er semestre5 5736 535- 15%CA 2ème semestre6 8575 415+ 27%CA annuel12 43011 950+ 4% Données consolidées non auditées Au dernier trimestre 2025, Spineway, spécialiste des implants innovants pour le traitement des pathologies de la colonne vertébrale (rachis), a bénéficié d’une accélération des ventes sur l...

 PRESS RELEASE

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sal...

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sales in Q4 2025 (+34%) Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros20252024Change as a %H1 revenue5,5736,535-15%H2 revenue6,8575,415+27%Full-year revenue12,43011,950+4% Unaudited consolidated data In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders d...

 PRESS RELEASE

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ES...

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie  Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboratio...

 PRESS RELEASE

Spineway : Revenue growth in the third quarter

Spineway : Revenue growth in the third quarter Ecully, October 14, 2025 – 6:30 p.m. SPINEWAYRevenue growth in the third quarter In thousands of euros20252024Change as a %Q3 revenue3,0452,575   +18%Q2 revenue2,7453,465-21% Q1 revenue2,8283,070-8%9M revenue8,6189,110      -5% Unaudited consolidated data The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, benefited, in line with its expectations, from a deferral of orders from major accounts to the third quarter of 2025 and generated revenue of €3.0 million over the period, up from €2.6 millio...

 PRESS RELEASE

SPINEWAY : Croissance du chiffre d’affaires au 3ème trimestre

SPINEWAY : Croissance du chiffre d’affaires au 3ème trimestre Ecully, le 14 octobre 2025 – 18h30 SPINEWAYCroissance du chiffre d’affaires au 3ème trimestre En milliers d’euros20252024Variationen %CA 3ème trimestre3 0452 575   + 18%CA 2ème trimestre2 7453 465- 21%CA 1er trimestre2 8283 070      - 8%CA 9 mois8 6189 110       - 5% Données consolidées non auditées Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), a bénéficié, conformément à ses anticipations, d’un report des commandes de grands comptes sur le 3ème trimes...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch